Kazuyuki Numakura

Asahikawa, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 170 publications

Outcome of Eight-Year-Experiences of BCG Intravesical Instillation Therapy in Patients with Non-Muscle Invasive Bladder Cancer in Asahikawa Medical University Hospital

Outcome of Eight-Year-Experiences of BCG Intravesical Instillation Therapy in Patients with Non-Muscle Invasive Bladder Cancer in Asahikawa Medical University Hospital

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: August 04, 2026

Subsequent systemic therapy initiation after first-line discontinuation in metastatic renal cell carcinoma: insights from a Japanese real-world cohort.

Subsequent systemic therapy initiation after first-line discontinuation in metastatic renal cell carcinoma: insights from a Japanese real-world cohort.

Journal: ESMO real world data and digital oncology

Published: July 13, 2026

Visualizing Baseline Eligibility Across Locally Advanced or Metastatic Urothelial Cancer Trials and Real-World Cohorts.

Visualizing Baseline Eligibility Across Locally Advanced or Metastatic Urothelial Cancer Trials and Real-World Cohorts.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: May 11, 2026

Real-world Outcomes of Adjuvant Nivolumab in High-risk Bladder and Upper Tract Urothelial Carcinoma after Radical Surgery.

Real-world Outcomes of Adjuvant Nivolumab in High-risk Bladder and Upper Tract Urothelial Carcinoma after Radical Surgery.

Journal: European urology open science

Published: April 19, 2026

Visualizing eligibility gaps between muscle-invasive bladder cancer trials and real-world patients.

Visualizing eligibility gaps between muscle-invasive bladder cancer trials and real-world patients.

Journal: Japanese journal of clinical oncology

Published: March 24, 2026

Association of EVITA with safety in advanced urothelial carcinoma: A multicenter real-world study.

Association of EVITA with safety in advanced urothelial carcinoma: A multicenter real-world study.

Journal: Urologic oncology

Published: February 16, 2026

A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J-ENCORE Study.

A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J-ENCORE Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: January 18, 2026

Optimizing management of small renal masses: a patient-centered approach to minimize overtreatment.

Optimizing management of small renal masses: a patient-centered approach to minimize overtreatment.

Journal: Japanese journal of clinical oncology

Published: January 12, 2026

Presenting postoperative mortality as percentages and natural frequencies (1-in-N) in major urologic cancer surgeries.

Presenting postoperative mortality as percentages and natural frequencies (1-in-N) in major urologic cancer surgeries.

Journal: Urologic oncology

Published: December 27, 2025

Neoadjuvant Chemohormonal Therapy for Patients With Very-high Risk Localized Prostate Cancer in Clinical Stages T2 and T3a.

Neoadjuvant Chemohormonal Therapy for Patients With Very-high Risk Localized Prostate Cancer in Clinical Stages T2 and T3a.

Journal: In vivo (Athens, Greece)

Published: December 01, 2025

Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.

Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: November 17, 2025

Deferred Cytoreductive Nephrectomy in Unresectable/Metastatic Renal Cell Carcinoma: A Real-World Multicenter Retrospective Study.

Deferred Cytoreductive Nephrectomy in Unresectable/Metastatic Renal Cell Carcinoma: A Real-World Multicenter Retrospective Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: October 14, 2025

Showing 1-12 of 170

Last Updated: 09/26/2026